Article Text

See original article:

other Versions


Autoantibodies in Lung Cancer - possibilities for early detection and subsequent cure
  1. Caroline J Chapman (caroline.chapman{at}
  1. University of Nottingham, United Kingdom
    1. Andrea Murray (andrea.murray{at}
    1. Oncimmune Ltd, United Kingdom
      1. Jane E McElveen (jane.mcelveen{at}
      1. Oncimmune Ltd, United Kingdom
        1. Ugur Sahin (sahin{at}
        1. Johannes Guttenberg University, Germany
          1. Ulrich Luxemburger (luxembur{at}
          1. Johannes Guttenberg University, Germany
            1. Özlem Türeci (tureci{at}
            1. Johannes Guttenberg University, Germany
              1. Rainer Wiewrodt (wiewrodt{at}
              1. Johannes Gutenberg University Medical Center, Germany
                1. Anthony C Barnes (tbarnes614{at}
                1. Oncimmune Ltd, United Kingdom
                  1. John FR Robertson (john.robertson{at}
                  1. University of Nottingham, United Kingdom


                    Background Individuals with lung cancer usually present at a late stage in the course of their disease when their chances of long term survival are low. At present there is little to offer for early diagnosis, even in individuals at high risk of developing the disease. Autoantibodies have been shown to be present in the circulation of individuals with various forms of solid tumour before cancer-associated antigens can be detected, and these molecules can be measured up to 5 years before symptomatic disease. This study aims to assess the potential of a panel of tumour-associated autoantibody profiles as an aid to other lung cancer screening modalities.

                    Methods Plasma from normal controls (n=50), patients with non small cell lung cancer (NSCLC) (n=82) and patients with small cell lung cancer (SCLC) (n=22) were investigated for the presence of autoantibodies to p53; c-myc; HER2; NY-ESO-1; CAGE; MUC1 and GBU4-5 by enzyme-linked immunosorbent assay.

                    Results Elevated levels of autoantibodies were seen to at least 1/7 antigens in 76% of all the lung cancer patient plasma tested, and 89% of node negative patients, with a specificity of 92%. There was no significant difference between the detection rates in the lung cancer subgroups, although more individuals with squamous cell carcinomas (92%) could be identified.

                    Conclusion Measurement of an autoantibody response to one or more tumour associated antigens in an optimised panel assay, could provide a sensitive and specific blood test to aid the early detection of lung cancer.

                    • Autoantibodies
                    • Diagnosis
                    • Lung Cancer
                    • Tumor Antigens
                    • Tumor markers

                    Statistics from

                    • web only appendix 63/3/228

                      Files in this Data Supplement:

                    Request permissions

                    If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.

                    Linked Articles

                    • Corrections
                      BMJ Publishing Group Ltd and British Thoracic Society